<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations and diagnosis of familial Mediterranean fever
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations and diagnosis of familial Mediterranean fever
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations and diagnosis of familial Mediterranean fever
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eldad Ben-Chetrit, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David S Pisetsky, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Siobhan M Case, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 01, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disorder characterized by recurrent bouts of fever and serosal inflammation. This topic will review the clinical manifestations and diagnosis of FMF. The epidemiology, genetics, pathophysiology, and management of FMF and an overview of periodic fever syndromes and other autoinflammatory diseases can be found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2634.html" rel="external">
          "Familial Mediterranean fever: Epidemiology, genetics, and pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2574.html" rel="external">
          "Management of familial Mediterranean fever"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5597.html" rel="external">
          "The autoinflammatory diseases: An overview"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Familial Mediterranean fever (FMF) is characterized by recurrent attacks of fever and serositis (eg, peritonitis, pleuritis, pericarditis, synovitis) or erysipelas-like erythema. Most patients with FMF experience their first attack in early childhood. The initial attack occurs before the ages of 10 and 20 years in 65 and 90 percent of cases, respectively [
         <a href="#rid1">
          1
         </a>
         ]. However, in rare cases, the initial attack can occur in individuals older than 50 years of age.
        </p>
        <p>
         The onset of fever and pain (due to serositis at one or more sites) is usually abrupt, peaking soon after the attack starts. Some patients have a stereotypic prodrome (an aura) before their attacks [
         <a href="#rid2">
          2
         </a>
         ]. This may include various constitutional and physical signs, such as restlessness at the site where the symptom is about to occur, anxiety, irritability, increased appetite, and taste alterations [
         <a href="#rid2">
          2
         </a>
         ]. Episodes last for one to three days and then resolve spontaneously. Patients are asymptomatic between attacks. The frequency of attacks is highly variable, even in a given patient. The intervals between episodes are irregular, ranging from a few days to several months.
        </p>
        <p>
         Usually, FMF patients cannot describe a consistent triggering event. Nevertheless, vigorous exercise, emotional stress, intercurrent infections, exposure to cold, surgery, and menstruation have been associated with an attack in some patients. During pregnancy, the course of FMF may worsen in about a third of the patients, improve in another third of patients, and remain unchanged in the rest [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Clinical manifestations of FMF vary among different populations (Middle Eastern patients versus European or Japanese patients) [
         <a href="#rid4">
          4
         </a>
         ]. In the Middle East, a typical case of FMF almost always includes recurrent attacks of fever with serositis (peritonitis, pleuritis, pericarditis, or synovitis) in one or more sites in a single attack. The characteristic skin manifestation of FMF is erysipelas-like erythema (no urticaria or maculopapular rash). Among Japanese or European patients with FMF, the frequency of fever and peritonitis is relatively low, while the presence of headache is quite common. Moreover, Japanese and European patients may display various types of skin rash, posing serious doubt about the diagnosis of FMF [
         <a href="#rid4">
          4
         </a>
         ]. These differences are mainly related to genotypic differences; a typical Middle Eastern FMF pattern is associated with exon 10 mutations. Atypical features of FMF (such as those seen in Japanese patients) are associated with non-exon 10 genetic variants [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3080624837">
         <span class="h2">
          Recurrent fever
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fever is one of the most constant characteristics of FMF and is present in almost all cases during attacks [
         <a href="#rid6">
          6
         </a>
         ]. In the majority of FMF patients, the temperature rises from 38° to 40°C (100.4° to 104°F), although mild attacks may be accompanied by a subfebrile temperature (37.5° to 38°C or 99.5° to 100.4°F). Typically, the duration of the fever is brief, lasting between 12 hours and three days. Fever may be the first and only symptom of FMF, especially in toddlers [
         <a href="#rid7">
          7
         </a>
         ]. In FMF patients who are treated with
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         , an acute attack may occur without fever.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Abdominal pain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Abdominal pain is a common manifestation of FMF; as an example, up to 95 percent of FMF patients in the Middle-East have episodic abdominal pain [
         <a href="#rid1">
          1
         </a>
         ]. Abdominal pain and tenderness may initially be localized and then progress to become more generalized. Since the cause of the abdominal pain is inflammation of the peritoneum, signs of peritonitis such as guarding, rebound tenderness, rigidity, and an adynamic ileus are often present. These findings can be mistaken for an acute surgical abdomen leading to diagnosis delay and sometimes even to futile operations. (See
         <a class="medical medical_review" href="/z/d/html/6862.html" rel="external">
          "Evaluation of the adult with abdominal pain", section on 'Urgent evaluation and/or surgical abdomen'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6454.html" rel="external">
          "Causes of acute abdominal pain in children and adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6434.html" rel="external">
          "Emergency evaluation of the child with acute abdominal pain"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Chest pain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Painful FMF attacks are localized to the chest in 33 to 84 percent of patients [
         <a href="#rid6">
          6
         </a>
         ]. This seems to vary based on genotypic differences, with a higher rate of pleuritic involvement in Armenian FMF patients compared with those from other parts of the world. Chest pain may be due to inflammation of the pleura or referred pain from subdiaphragmatic inflammation. Pleural inflammation typically manifests as unilateral chest pain that is worse with inspiration or coughing. Patients often have a small, transient pleural effusion. Fluid analysis is exudative, and neutrophils are dominant. In some patients, thickening and adhesion have been reported in the pleura as a result of repeated attacks. Episodes usually resolve within three days but may last up to one week. Concomitant pericarditis can also be observed in patients with pleuritis.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Joint pain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among non-Ashkenazi Jews with FMF, approximately 75 percent experience sudden attacks of articular pain, which may be precipitated by minor trauma or effort such as prolonged walking. The joint attacks are usually monoarticular, involving one of the large joints (knee, ankle, hip, or elbow). In rare cases, patients present with a migratory polyarthritis. Gradual resolution of the signs and symptoms occur after peaking in 24 to 48 hours. The synovial fluid analysis is typically sterile, with a nucleated white cell count ranging from 200 to &gt;100,000 white blood cells/mm
         <sup>
          3
         </sup>
         [
         <a href="#rid8">
          8
         </a>
         ]. The synovitis usually resolves completely without leading to joint destruction. However, some 5 to 10 percent of patients with FMF may experience protracted arthritis attacks affecting mainly the knees and hips, lasting more than a month, sometimes even years [
         <a href="#rid9">
          9,10
         </a>
         ]. Protracted hip arthritis may exhibit destructive characteristics. In trials, it has been shown that approximately 30 percent of patients with hip involvement required a total hip replacement [
         <a href="#rid9">
          9
         </a>
         ]. However, this complication is rarely seen since
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         became standardly used in the 1970s. (See
         <a class="medical medical_review" href="/z/d/html/1828.html" rel="external">
          "Synovial fluid analysis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2035.html" rel="external">
          "Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5613.html" rel="external">
          "Treatment of nontraumatic hip osteonecrosis (avascular necrosis of the femoral head) in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Erysipelas-like skin lesion
         </span>
         <span class="headingEndMark">
          —
         </span>
         An erysipelas-like skin lesion is reported in 12 to 40 percent of FMF patients [
         <a href="#rid11">
          11
         </a>
         ]. The lesion is typically 10 to 35 cm
         <sup>
          2
         </sup>
         in area, tender, raised, and erythematous and occurs on the lower leg, ankle, or dorsum of the foot, usually on one side  (
         <a class="graphic graphic_picture graphicRef111977" href="/z/d/graphic/111977.html" rel="external">
          picture 1
         </a>
         ). Lesions may be transiently warm without associated pain or tenderness. Erysipelas-like skin lesions may be the presenting feature of FMF in children and may be misdiagnosed as an infectious erysipelas, cellulitis, or ankle arthritis [
         <a href="#rid11">
          11,12
         </a>
         ]. Children with myalgia and erysipelas-like skin lesions during attacks are at increased risk for subclinical inflammation during attack-free intervals, as evidenced by the elevation of acute phase reactants [
         <a href="#rid13">
          13
         </a>
         ]. Recovery is spontaneous and does not require antibiotics. (See
         <a class="local">
          'Laboratory findings'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">
          "Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Other manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other rare manifestations of FMF include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exertional myalgia
         </strong>
         – Exercise-induced myalgia is a typical manifestation of FMF. It usually affects the lower limbs (thighs and calves) in children and adolescents with the disease. It does not have an episodic characteristic and is not controlled by treatment with
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         . It resolves with rest or treatment with nonsteroidal antiinflammatory drugs (NSAIDs). (See
         <a class="medical medical_review" href="/z/d/html/2574.html" rel="external">
          "Management of familial Mediterranean fever", section on 'Exertional myalgia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute pericarditis
         </strong>
         – Symptomatic acute pericarditis occurs in less than one percent of patients with FMF [
         <a href="#rid14">
          14
         </a>
         ]. In one study, the frequency of pericarditis was found to be 11-fold higher than in the general population [
         <a href="#rid15">
          15
         </a>
         ]. However, even in FMF, acute pericarditis is still a rare event. Clinical features of pericarditis include chest pain (sharp and pleuritic, improved by sitting up and leaning forward), pericardial friction rub, and widespread ST segment elevation on electrocardiogram [
         <a href="#rid15">
          15
         </a>
         ]. The length of such an attack is similar to or slightly longer (four to five days) than that of a typical FMF attack. Usually, recurrent attacks of FMF pericarditis do not lead to constrictive pericarditis. (See
         <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">
          "Acute pericarditis: Clinical presentation and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute scrotum
         </strong>
         – In children with FMF, acute scrotum is characterized by mostly unilateral painful and swollen scrotum. Operative findings show normal testes and epididymis and a thick and hyperemic tunica vaginalis, which is an extension of the peritoneum. Acute scrotum should be differentiated from testicular torsion and does not require surgical intervention. Acute scrotal swelling and tenderness due to orchitis is a rare manifestation of FMF [
         <a href="#rid16">
          16,17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6873.html" rel="external">
          "Acute scrotal pain in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Protracted
         </strong>
         <strong>
          febrile myalgia
         </strong>
         – Patients with FMF can present with protracted bouts of febrile myalgia that can last up to eight weeks. Febrile myalgias usually involve the lower extremities but, in some cases, may be more diffuse [
         <a href="#rid18">
          18
         </a>
         ]. Patients with febrile myalgia have an increased erythrocyte sedimentation rate but a normal serum creatine kinase level and a normal electromyogram (EMG). Protracted febrile myalgia is associated with a severe course of FMF and homozygosity for M694V mutation in the
         <em>
          MEFV
         </em>
         gene. Although the etiology is not clear, febrile myalgia is considered to be a "vasculitic manifestation" of FMF. However, frank vasculitis was not found in any of the muscle biopsies taken from affected patients [
         <a href="#rid19">
          19
         </a>
         ].
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          Colchicine
         </a>
         does not prevent or treat protracted febrile myalgia. (See
         <a class="medical medical_review" href="/z/d/html/2574.html" rel="external">
          "Management of familial Mediterranean fever", section on 'Management of specific features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Headache and aseptic meningitis
         </strong>
         – Headache may accompany acute FMF attacks and is usually mild. It is more common among patients with FMF who are from areas outside of the Middle East. A more severe type of headache in the form of recurrent aseptic meningitis has also been reported, but it is still unclear whether this clinical feature is part of FMF [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1296.html" rel="external">
          "Aseptic meningitis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rash and oral ulcers
         </strong>
         – Skin rash and oral ulcers have been reported in European and Japanese patients [
         <a href="#rid5">
          5,21
         </a>
         ]. These are not typical features of FMF and may present in patients with other autoinflammatory diseases, such as tumor necrosis factor (TNF) receptor-1 associated periodic syndrome (TRAPS), cryopyrin-associated periodic syndrome (CAPS), and mevalonate kinase deficiency (MKD), who were wrongly diagnosed with FMF. Very rarely, skin rash may be seen in cases of atypical FMF [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5597.html" rel="external">
          "The autoinflammatory diseases: An overview"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Associated diseases
         </strong>
         – Systemic nongranulomatous vasculitides such as immunoglobulin A vasculitis (IgAV; Henoch-Schönlein purpura [HSP]) and classical polyarteritis nodosa have a higher incidence among FMF patients [
         <a href="#rid22">
          22
         </a>
         ]. The possibility that these diseases are actually rare manifestations of FMF has also been suggested [
         <a href="#rid23">
          23
         </a>
         ]. In most of these cases, the patients carry at least a single M694V mutation in the
         <em>
          MEFV
         </em>
         gene. While some studies suggest that Behçet syndrome, ankylosing spondylitis, inflammatory bowel diseases, and multiple sclerosis are more prevalent in FMF patients, these associations remain controversial [
         <a href="#rid24">
          24-26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6406.html" rel="external">
          "IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8245.html" rel="external">
          "Clinical manifestations and diagnosis of polyarteritis nodosa in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8223.html" rel="external">
          "Clinical manifestations and diagnosis of Behçet syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          LABORATORY FINDINGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute attacks of familial Mediterranean fever (FMF) are accompanied by elevation of serum markers of systemic inflammation. Common laboratory findings include leukocytosis with a predominance of neutrophils, elevated erythrocyte sedimentation rate (ESR), and elevated acute phase reactants such as C-reactive protein (CRP), serum amyloid A (SAA) protein, and fibrinogen. The presence of otherwise unexplained proteinuria in between attacks may suggest renal amyloidosis. However, FMF patients with proteinuria who are treated with
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         should be evaluated for causes other than amyloidosis. (See
         <a class="medical medical_review" href="/z/d/html/3120.html" rel="external">
          "Renal amyloidosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          LONG-TERM COMPLICATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Secondary (AA) amyloidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Progressive secondary (AA) amyloidosis is a major cause of mortality in patients with familial Mediterranean fever (FMF) [
         <a href="#rid27">
          27
         </a>
         ]. Rarely, patients can present with renal amyloidosis as the first and only manifestation of FMF (also known as FMF type II) [
         <a href="#rid28">
          28
         </a>
         ]. Patients with renal amyloidosis can present with asymptomatic proteinuria or clinically apparent nephrotic syndrome and gradually develop progressive nephropathy with end-stage kidney disease. End-stage kidney disease develops 2 to 13 years after the onset of proteinuria [
         <a href="#rid1">
          1
         </a>
         ]. Amyloid deposition can also occur in the spleen, liver, and gastrointestinal tract and subsequently in the heart, thyroid, and testes. Patients with gastrointestinal tract amyloidosis usually present with diarrhea and malabsorption. The clinical manifestations of amyloidosis are discussed in detail, separately. (See
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3120.html" rel="external">
          "Renal amyloidosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2642.html" rel="external">
          "Gastrointestinal amyloidosis: Clinical manifestations, diagnosis, and management"
         </a>
         .)
        </p>
        <p>
         In some patients, there is poor correlation between the severity or frequency of attacks of FMF and the extent of amyloidosis. It is unclear whether the deposition of amyloid is due solely to the byproducts of recurrent systemic inflammation or whether there is a contribution from the underlying genetic defect. In the pre-colchicine period, in FMF patients aged 40 years and above, the incidence of amyloidosis has been reported in 60 to 75 percent of the patients [
         <a href="#rid29">
          29
         </a>
         ]. The incidence of amyloidosis has markedly decreased with the regular use of
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         . Nevertheless, amyloidosis complications are still a problem, especially in communities where the disease is common and access to colchicine is limited [
         <a href="#rid30">
          30
         </a>
         ]. In two large population-based studies conducted in Turkey, the frequencies of amyloidosis were reported as 12.9 [
         <a href="#rid31">
          31
         </a>
         ] and 8.6 percent [
         <a href="#rid32">
          32
         </a>
         ]. Additional significant risk factors for developing amyloidosis in FMF patients include: male sex, a positive family history of AA amyloidosis, and the country of origin (with higher risk for patients from the eastern Mediterranean and Armenia) [
         <a href="#rid33">
          33
         </a>
         ]. The term "country of origin" may include carriage of common genetic factors, general quality of health services, and access to medical treatment (colchicine, anti-interleukin [IL] 1 agents, etc).
        </p>
        <p>
         Analysis of the phenotypic expressions of the two most frequent mutations of the
         <em>
          MEFV
         </em>
         gene, V726A and M694V, suggested that amyloidosis and severe arthritis are much more frequently observed with the latter defect [
         <a href="#rid34">
          34,35
         </a>
         ]. Other modifier proteins have also been implicated. Patients without amyloidosis are more likely to have beta and gamma alleles of type 1 serum amyloid A (
         <em>
          SAA1
         </em>
         ) gene, suggesting that these alleles may be protective [
         <a href="#rid35">
          35
         </a>
         ]. Carrying the alpha allele is associated with a three- to fourfold higher risk for developing amyloidosis. (See
         <a class="medical medical_review" href="/z/d/html/2634.html" rel="external">
          "Familial Mediterranean fever: Epidemiology, genetics, and pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5619.html" rel="external">
          "Pathogenesis of AA amyloidosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2634.html" rel="external">
          "Familial Mediterranean fever: Epidemiology, genetics, and pathogenesis", section on 'Other genetic factors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H505256397">
         <span class="h2">
          Small bowel obstruction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recurrent attacks of peritonitis may lead to adhesions and small bowel obstruction [
         <a href="#rid36">
          36
         </a>
         ]. Treatment with
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         , which controls the FMF attacks, is also effective in preventing the development of peritoneal adhesions [
         <a href="#rid37">
          37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8037.html" rel="external">
          "Etiologies, clinical manifestations, and diagnosis of mechanical small bowel obstruction in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/89300.html" rel="external">
          "Management of small bowel obstruction in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H505256403">
         <span class="h2">
          Infertility
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the pre-colchicine era, pelvic adhesions and fallopian tube obstruction led to mechanical infertility in female patients. In men, fertility may be decreased due to azoospermia from testicular amyloidosis or impairment in sperm penetration. In very rare cases,
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         may cause transient oligospermia or azoospermia [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7473.html" rel="external">
          "Causes of male infertility"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5408.html" rel="external">
          "Female infertility: Causes", section on 'Fallopian tube abnormalities/pelvic adhesions'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H369706896">
         <span class="h2">
          When to consider the diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of familial Mediterranean fever (FMF) should be suspected in individuals with recurrent febrile episodes accompanied by peritonitis, synovitis or pleuritis, recurrent erysipelas-like erythema, repeated laparotomies for an acute abdomen with no identifiable underlying pathology, a first-degree relative with FMF, and/or membership in an at-risk ethnic group. FMF has been described primarily in non-Ashkenazi Jews, Armenians, Turks, Arabs, Greeks, and Italians. However, the disease is not restricted to these groups. In the United States, for example, FMF is frequently encountered in Ashkenazi Jews. In Japan, there are more than 500 FMF patients of original ethnicity. Because cases of FMF have been diagnosed in a wide variety of other populations, ancestry should not be used to rule out the diagnosis if other clinical characteristics are present [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2634.html" rel="external">
          "Familial Mediterranean fever: Epidemiology, genetics, and pathogenesis", section on 'Epidemiology'
         </a>
         and
         <a class="local">
          'Our diagnostic approach'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H369706902">
         <span class="h2">
          Our diagnostic approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         In endemic countries for FMF (eg, the Middle East, Armenia) the diagnosis is made on the basis of clinical symptoms and supported by family history. In countries where FMF is relatively uncommon, genetic testing is crucial for the diagnosis. Genetic testing for FMF serves to support the diagnosis in patients who meet clinical criteria for FMF, to counsel at-risk relatives, and to guide the therapeutic approach [
         <a href="#rid39">
          39
         </a>
         ]. In individuals who meet clinical criteria for FMF but in whom genetic testing is not diagnostic (only one or no pathogenic
         <em>
          MEFV
         </em>
         mutation), the diagnosis of FMF is supported by a six-month trial of
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         therapy that results in a relief of attacks and recurrence after cessation of treatment [
         <a href="#rid40">
          40
         </a>
         ]. However, a
         <strong>
          definitive diagnosis
         </strong>
         of FMF can be made only on a genetic basis. This is based on the observation that additional autoinflammatory diseases (eg, tumor necrosis factor [TNF] receptor-1 associated periodic syndrome [TRAPS] and mevalonate kinase deficiency [MKD, hyperimmunoglobulin D syndrome]) may present clinically identical to FMF [
         <a href="#rid41">
          41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2574.html" rel="external">
          "Management of familial Mediterranean fever", section on 'Initial management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2634.html" rel="external">
          "Familial Mediterranean fever: Epidemiology, genetics, and pathogenesis", section on 'MEFV gene mutations'
         </a>
         .)
        </p>
        <p>
         We diagnose FMF in patients with
         <strong>
          typical attacks
         </strong>
         and the following combination of criteria  (
         <a class="graphic graphic_table graphicRef67666" href="/z/d/graphic/67666.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ≥1 major criteria
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ≥2 minor criteria
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         1 minor plus 5 supportive criteria
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         1 minor criterion plus ≥4 of the first 5 supportive criteria
        </p>
        <p>
        </p>
        <p>
         <strong>
          Typical attacks
         </strong>
         are defined by the presence of all of the following features: pain due to serositis, recurrence of attacks (≥3 of the same type), presence of fever (rectal temperature of 38°C or higher), and short duration (lasting between 12 hours to 3 days). Attacks of fever alone are considered typical if they appear to be recurrent and of short duration and have no other detectable cause [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5352429">
         <span class="h3">
          Major criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Major criteria for the clinical diagnosis of FMF consist of a typical attack involving one or more of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peritonitis (generalized)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pleuritis (unilateral) or pericarditis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monoarthritis (hip, knee, ankle, or elbow)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fever alone
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5352441">
         <span class="h3">
          Minor criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Minor criteria for the clinical diagnosis of FMF consist of an incomplete attack involving one or more of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abdomen
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chest
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monoarthritis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exertional leg pain
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Favorable response to
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5352448">
         <span class="h3">
          Supportive criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Supportive criteria for FMF include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Family history of FMF
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Appropriate ethnic origin
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age &lt;20 years at disease onset
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe attack requiring bed rest
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Spontaneous remission of attack
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptom-free interval between attacks
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Attacks associated with transient inflammatory response with one or more abnormal laboratory results for white blood cell count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), serum amyloid A, and/or fibrinogen
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Episodic proteinuria/hematuria
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Negative laparotomy or removal of normal appendix
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Consanguinity of parents
        </p>
        <p>
        </p>
        <p>
         This approach is consistent with criteria developed at the Tel Hashomer Medical Center in Israel  (
         <a class="graphic graphic_table graphicRef67666" href="/z/d/graphic/67666.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid42">
          42
         </a>
         ]. These remain the most widely used and well-accepted criteria, although several other diagnostic criteria have also been proposed [
         <a href="#rid43">
          43-45
         </a>
         ]. The sensitivity and specificity for the diagnosis of FMF varies based on the number of criteria that are met  (
         <a class="graphic graphic_algorithm graphicRef77816" href="/z/d/graphic/77816.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid42">
          42-45
         </a>
         ]. Notably, however, these criteria do not include the results of genetic analyses that are an essential tool for the definitive diagnosis of FMF.
        </p>
        <p>
         Subsequently, newer
         <strong>
          classification criteria
         </strong>
         for FMF have been proposed [
         <a href="#rid46">
          46
         </a>
         ]. These criteria require the presence of confirmatory
         <em>
          MEFV
         </em>
         genotype and at least one of the following four clinical features: duration of episodes one to three days, arthritis, chest pain, or abdominal pain. Alternatively, in cases with no confirmatory
         <em>
          MEFV
         </em>
         genotype, the patient should have at least two of the above features. Confirmatory genotype means carriage of pathogenic or likely pathogenic mutations as homozygotes or compound heterozygotes. Non-confirmatory genotype means carrying a single mutation (heterozygotes). The scoring of the pathogenicity of the genetic variants has been published recently [
         <a href="#rid47">
          47
         </a>
         ]. For example, exon 10 mutations in the
         <em>
          MEFV
         </em>
         gene (eg, M694V, M680I, A726V) are considered pathogenic or likely pathogenic variants, whereas exon 1 or 2 mutations (eg, E167D, P706P) are considered benign or likely benign variants. These classification criteria are recommended for inclusion of patients in translational and clinical studies and should not be used as diagnostic criteria. However, they can be supportive for diagnosis of FMF by excluding other hereditary fever syndromes.
        </p>
        <p>
         Most individuals carrying a single pathogenic mutation (heterozygotes) remain asymptomatic for life. As a matter of fact, only approximately 2 percent of them will present with full blown FMF disease. In many cases, these patients display the disease only in their second or third decade of life. Few of them may become "attack-free" after several years of an active disease.
        </p>
        <p>
         In addition, there are rare individuals carrying two pathogenic genetic variants who remain asymptomatic (also known as FMF type III). It is not possible to predict whether they will develop the disease later in life [
         <a href="#rid48">
          48
         </a>
         ]. These individuals should be followed in the FMF clinic in order to watch for evolving symptoms and the potential need to start treatment.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genetic testing is used to support the diagnosis of FMF and to exclude other autoinflammatory diseases that may clinically mimic FMF. FMF is usually inherited as an autosomal recessive trait. The detection of two pathogenic mutations in the
         <em>
          MEFV
         </em>
         gene in an individual confirms the diagnosis. However, in Middle Eastern communities, approximately 33 percent of patients who meet clinical criteria for FMF have only one identifiable mutation [
         <a href="#rid40">
          40,49
         </a>
         ]. Furthermore, 10 to 20 percent of patients who meet clinical diagnostic criteria do not carry any known mutation for FMF [
         <a href="#rid50">
          50,51
         </a>
         ]. In these cases, the diagnosis of FMF is probable rather than definitive. (See
         <a class="medical medical_review" href="/z/d/html/2634.html" rel="external">
          "Familial Mediterranean fever: Epidemiology, genetics, and pathogenesis", section on 'MEFV gene mutations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3822897885">
         <span class="h2">
          Investigational approaches
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several laboratory tests have been proposed as adjuncts to genetic testing. One test is an ex vivo
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         functional assay performed on mononuclear cells in the peripheral blood [
         <a href="#rid52">
          52
         </a>
         ]. The other assay quantifies the effect of a selective kinase inhibitor (UCN-01) on inflammasome activation [
         <a href="#rid53">
          53
         </a>
         ]. The main limitation to these tests is their complexity and therefore limited availability. In addition, these tests would not eliminate the need for genetic testing.
        </p>
        <p class="headingAnchor" id="H505255655">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis varies with the patient's predominant clinical features.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Periodic fever syndromes
         </strong>
         – Familial Mediterranean fever (FMF) must be distinguished from other hereditary periodic fever syndromes since they all share the common symptom of periodic or episodic fever. However, each of the periodic fever syndromes is also accompanied by a constellation of clinical features that differ from those of FMF. The other periodic fever syndromes include periodic fever with aphthous stomatitis, pharyngitis, and adenitis (PFAPA); tumor necrosis factor (TNF) receptor-1 associated periodic syndrome (TRAPS); hyperimmunoglobulin D syndrome (HIDS or mevalonate kinase deficiency [MKD]); and cryopyrin-associated periodic syndromes (CAPS). PFAPA, as the name suggests, differs from FMF in that patients present with aphthous ulcerations, pharyngitis, and lymphadenopathy. In addition, the attacks are periodic and appear every three or four weeks and last three to seven days. The febrile attacks in patients with TRAPS are typically accompanied by conjunctivitis and periorbital edema in addition to focal migratory myalgias and rash. The attacks of TRAPS usually last from 7 to 21 days. Patients with MKD generally have pharyngitis, painful cervical lymphadenopathy, abdominal pain, and vomiting or diarrhea in the setting of elevated levels of immunoglobulin (Ig) D. Sometimes, the flares of MKD are elicited by vaccinations, and the attack duration is usually between three to seven days. CAPS represent a family of syndromes in which urticarial rashes and sometimes neurologic involvement accompany episodic fevers. The attack duration in CAPS is usually shorter, lasting one to two days. (See
         <a class="medical medical_review" href="/z/d/html/5597.html" rel="external">
          "The autoinflammatory diseases: An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5585.html" rel="external">
          "Cryopyrin-associated periodic syndromes and related disorders"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Systemic juvenile idiopathic arthritis/adult-onset Still's disease
         </strong>
         – Another diagnostic consideration is the febrile-onset arthritis in childhood known as systemic juvenile idiopathic arthritis and in adults as adult-onset Still's disease. Patients with these conditions present with features including high-spiking fevers, rash, serositis, and lymphadenopathy. Arthritis is often evident at onset but may sometimes present weeks or months later. Unlike FMF, patients with these conditions usually have a specific daily fever pattern that does not resolve after several days. (See
         <a class="medical medical_review" href="/z/d/html/6413.html" rel="external">
          "Systemic juvenile idiopathic arthritis: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5611.html" rel="external">
          "Clinical manifestations and diagnosis of adult-onset Still's disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Systemic vasculitis involving the abdomen
         </strong>
         – A variety of vasculitides can present with severe abdominal pain, including polyarteritis nodosa, immunoglobulin A vasculitis (IgAV; Henoch-Schönlein purpura [HSP]), and Behçet syndrome. However, these vasculitides can be distinguished from FMF by the presence of multiorgan system involvement with findings such as cutaneous small vessel vasculitis and glomerulonephritis. Moreover, the flares of these diseases do not last one to three days and resolve spontaneously. (See
         <a class="medical medical_review" href="/z/d/html/8245.html" rel="external">
          "Clinical manifestations and diagnosis of polyarteritis nodosa in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6406.html" rel="external">
          "IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8223.html" rel="external">
          "Clinical manifestations and diagnosis of Behçet syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Systemic rheumatic diseases
         </strong>
         – Fever, serositis, and arthritis can be the predominant manifestations of other systemic rheumatic diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Unlike FMF, patients with SLE have antinuclear antibodies (ANA) along with possible hypocomplementemia, glomerulonephritis, and cytopenia. RA can generally be distinguished from FMF by the pattern of a symmetric polyarthritis of the small joints of the hands and feet, and sometimes by the presence of a positive rheumatoid factor and/or anticyclic citrullinated peptide antibody. Palindromic rheumatism may cause a diagnostic dilemma in endemic countries for FMF since both clinical conditions have recurrent attacks of arthritis and fever. The presence of extraarticular features of FMF and genetic testing may help in making the exact diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">
          "Clinical manifestations and diagnosis of systemic lupus erythematosus in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7504.html" rel="external">
          "Diagnosis and differential diagnosis of rheumatoid arthritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection
         </strong>
         – A number of infections can mimic FMF but can be usually distinguished from FMF with blood cultures and/or serologic assays. Organisms that can cause subacute or chronic infections are the ones most likely to imitate FMF. Relapsing fever, caused by spirochetes of the
         <em>
          Borrelia
         </em>
         genus, is an arthropod-borne infection that causes recurrent episodes of fever (see
         <a class="medical medical_review" href="/z/d/html/7897.html" rel="external">
          "Clinical features, diagnosis, and management of relapsing fever"
         </a>
         ). Human parvovirus B19 can also cause flu-like symptoms and arthralgias or arthritis (see
         <a class="medical medical_review" href="/z/d/html/8272.html" rel="external">
          "Clinical manifestations and diagnosis of parvovirus B19 infection"
         </a>
         ). Similarly, acute rheumatic fever may also pose a diagnostic dilemma and can be differentiated from FMF based upon the episodic nature of fever, the different skin involvement (erysipelas-like erythema), and genetic testing [
         <a href="#rid54">
          54
         </a>
         ]. A variety of other infectious sources that can lead to a persistent or recurrent fever are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2737.html" rel="external">
          "Fever of unknown origin in adults: Etiologies"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Malignancy
         </strong>
         – Recurrent fever can also be the predominant manifestation of malignancies such as lymphoma, leukemia, or myelodysplastic syndromes. However, monoclonal expansion of B and T cells (as assessed by immunophenotyping), monocytosis, or macrocytosis can distinguish these malignancies from FMF. Patients with lymphoma also typically have additional findings such as splenomegaly, lymphadenopathy, or increased lactate dehydrogenase levels. (See
         <a class="medical medical_review" href="/z/d/html/2736.html" rel="external">
          "Fever of unknown origin in adults: Evaluation and management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5993.html" rel="external">
          "Fever of unknown origin in children: Evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other causes of abdominal pain
         </strong>
         – Other causes of acute abdominal pain can mimic the abdominal pain associated with FMF, such as appendicitis, cholecystitis, pancreatitis, and small bowel obstruction. Genetic disorders that are associated with recurrent bouts of abdominal pain include acute intermittent porphyria, hereditary angioedema, and genetically conferred hypertriglyceridemia. Unlike FMF, these conditions do not usually present with episodic fevers and arthritis. The approach to the patient with abdominal pain is discussed in detail, separately. (See
         <a class="medical medical_review" href="/z/d/html/6862.html" rel="external">
          "Evaluation of the adult with abdominal pain"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6454.html" rel="external">
          "Causes of acute abdominal pain in children and adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6434.html" rel="external">
          "Emergency evaluation of the child with acute abdominal pain"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/111.html" rel="external">
          "Chronic abdominal pain in children and adolescents: Approach to the evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H711931285">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/121582.html" rel="external">
          "Society guideline links: Familial Mediterranean fever"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disorder characterized by recurrent bouts of fever and serosal inflammation. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – Recurrent attacks are characterized by abrupt onset of fever and severe pain due to serositis at one or more sites. Serositis may result in abdominal, chest, or joint pain due to peritonitis, pleuritis, or synovitis, respectively. Episodes last for one to three days and then resolve spontaneously. In between attacks, patients are asymptomatic. Most patients with FMF experience their first attack in early childhood. The initial attack occurs before the ages of 10 and 20 years in 65 and 90 percent of cases, respectively. Other manifestations include an erysipelas-like erythema, which mimics cellulitis in the ankle or dorsum of the foot (unilaterally), and exertional myalgia. Rare manifestations include acute pericarditis, acute scrotum, and protracted febrile myalgia. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory abnormalities
         </strong>
         – Acute attacks of FMF are accompanied by elevation in many of the serum markers of systemic inflammation. Common laboratory findings include leukocytosis with a predominance of neutrophils, elevated erythrocyte sedimentation rate (ESR), and elevated acute phase reactants such as C-reactive protein (CRP), serum amyloid A protein, and fibrinogen. In FMF patients not treated with
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         , the presence of proteinuria is suggestive of renal amyloidosis. However, in those treated with colchicine, a thorough investigation is warranted in order to evaluate for causes other than amyloidosis. (See
         <a class="local">
          'Laboratory findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Long-term complications
         </strong>
         – Complications of FMF include secondary (AA) amyloidosis, small bowel obstruction, and infertility. The most frequent site of amyloid deposition is the kidney, although amyloid deposition can also occur in the spleen, liver, and gastrointestinal tract and subsequently in the heart, thyroid, and testes. Rarely, renal amyloidosis can be the first and only manifestation of FMF (also known as FMF type II). Patients with renal amyloidosis can present with asymptomatic proteinuria or clinically apparent nephrotic syndrome and gradually develop progressive nephropathy with end-stage kidney disease. (See
         <a class="local">
          'Long-term complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of FMF should be suspected in individuals with recurrent febrile episodes accompanied by peritonitis, synovitis or pleuritis, recurrent erysipelas-like erythema, repeated laparotomies for an acute abdomen with no identifiable underlying pathology, a first-degree relative with FMF, and/or membership in an at-risk ethnic group. For patients living in endemic countries for FMF (eg, the Middle East, Armenia), the diagnosis is made on the basis of clinical symptoms and supported by family history  (
         <a class="graphic graphic_table graphicRef67666" href="/z/d/graphic/67666.html" rel="external">
          table 1
         </a>
         ); genetic testing is used to further confirm the diagnosis. In countries where FMF is relatively uncommon, genetic testing is crucial for the diagnosis. In individuals who meet clinical criteria for FMF but in whom genetic testing is not diagnostic (only one or no pathogenic
         <em>
          MEFV
         </em>
         mutation), the diagnosis of FMF is supported by a six-month trial of
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         therapy, which results in a relief of attacks and recurrence after cessation of treatment. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis of FMF varies with the patient's predominant clinical features and includes other periodic fever syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease, systemic vasculitides involving the abdomen (eg, polyarteritis nodosa, immunoglobulin A vasculitis, Behçet syndrome), systemic lupus erythematosus, rheumatoid arthritis, rheumatic fever, a variety of infections, and malignancy. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H112965999">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editorial staff at UpToDate acknowledge Peter M Rosenberg, MD, and Stephen E Goldfinger, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967; 43:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lidar M, Yaqubov M, Zaks N, et al. The prodrome: a prominent yet overlooked pre-attack manifestation of familial Mediterranean fever. J Rheumatol 2006; 33:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eviatar T, Zaks N, Kukuy OL, et al. The effect of pregnancy on disease course in FMF. Pediatr Rheumatol Online J 2013; 11(Suppl 1):A63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben-Chetrit E, Yazici H. Familial Mediterranean fever: different faces around the world. Clin Exp Rheumatol 2019; 37 Suppl 121:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kishida D, Nakamura A, Yazaki M, et al. Genotype-phenotype correlation in Japanese patients with familial Mediterranean fever: differences in genotype and clinical features between Japanese and Mediterranean populations. Arthritis Res Ther 2014; 16:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben-Chetrit E, Touitou I. Familial mediterranean Fever in the world. Arthritis Rheum 2009; 61:1447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Padeh S, Livneh A, Pras E, et al. Familial Mediterranean fever in children presenting with attacks of fever alone. J Rheumatol 2010; 37:865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Gonzalez A, Weisman MH. The arthritis of familial Mediterranean fever. Semin Arthritis Rheum 1992; 22:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uthman I. The arthritis of familial Mediterranean fever. J Rheumatol 2005; 32:2278; author reply 2278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sneh E, Pras M, Michaeli D, et al. Protracted arthritis in familial Mediterranean fever. Rheumatol Rehabil 1977; 16:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lidar M, Doron A, Barzilai A, et al. Erysipelas-like erythema as the presenting feature of familial Mediterranean fever. J Eur Acad Dermatol Venereol 2013; 27:912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Majeed HA, Quabazard Z, Hijazi Z, et al. The cutaneous manifestations in children with familial Mediterranean fever (recurrent hereditary polyserositis). A six-year study. Q J Med 1990; 75:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bayram MT, Çankaya T, Bora E, et al. Risk factors for subclinical inflammation in children with Familial Mediterranean fever. Rheumatol Int 2015; 35:1393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kucuk A, Gezer IA, Ucar R, Karahan AY. Familial Mediterranean Fever. Acta Medica (Hradec Kralove) 2014; 57:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kees S, Langevitz P, Zemer D, et al. Attacks of pericarditis as a manifestation of familial Mediterranean fever (FMF). QJM 1997; 90:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drenth JP, van der Meer JW. Hereditary periodic fever. N Engl J Med 2001; 345:1748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eshel G, Vinograd I, Barr J, Zemer D. Acute scrotal pain complicating familial Mediterranean fever in children. Br J Surg 1994; 81:894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ertekin V, Selimoğlu MA, Alp H, Yilmaz N. Familial Mediterranean fever protracted febrile myalgia in children: report of two cases. Rheumatol Int 2005; 25:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langevitz P, Zemer D, Livneh A, et al. Protracted febrile myalgia in patients with familial Mediterranean fever. J Rheumatol 1994; 21:1708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Capron J, Grateau G, Steichen O. Is recurrent aseptic meningitis a manifestation of familial Mediterranean fever? A systematic review. Clin Exp Rheumatol 2013; 31:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gattorno M, Sormani MP, D'Osualdo A, et al. A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum 2008; 58:1823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rigante D, Lopalco G, Tarantino G, et al. Non-canonical manifestations of familial Mediterranean fever: a changing paradigm. Clin Rheumatol 2015; 34:1503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben-Chetrit E, Yazici H. Non-thrombocytopenic purpura in familial Mediterranean fever-comorbidity with Henoch-Schönlein purpura or an additional rare manifestation of familial Mediterranean fever? Rheumatology (Oxford) 2016; 55:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cosan F, Ustek D, Oku B, et al. Association of familial Mediterranean fever-related MEFV variations with ankylosing spondylitis. Arthritis Rheum 2010; 62:3232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watad A, Bragazzi NL, Adawi M, et al. FMF Is Associated With a Wide Spectrum of MHC Class I- and Allied SpA Disorders but Not With Classical MHC Class II-Associated Autoimmune Disease: Insights From a Large Cohort Study. Front Immunol 2019; 10:2733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akman-Demir G, Gul A, Gurol E, et al. Inflammatory/demyelinating central nervous system involvement in familial Mediterranean fever (FMF): coincidence or association? J Neurol 2006; 253:928.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005; 5:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heller H, Sohar E, Gafni J, Heller J. Amyloidosis in familial Mediterranean fever. An independent genetically determined character. Arch Intern Med 1961; 107:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gafni J, Ravid M, Sohar E. The role of amyloidosis in familial mediterranean fever. A population study. Isr J Med Sci 1968; 4:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet 1998; 351:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tunca M, Akar S, Onen F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 2005; 84:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasifoglu T, Bilge SY, Sari I, et al. Amyloidosis and its related factors in Turkish patients with familial Mediterranean fever: a multicentre study. Rheumatology (Oxford) 2014; 53:741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Touitou I, Sarkisian T, Medlej-Hashim M, et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007; 56:1706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell 1997; 90:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Medlej-Hashim M, Delague V, Chouery E, et al. Amyloidosis in familial Mediterranean fever patients: correlation with MEFV genotype and SAA1 and MICA polymorphisms effects. BMC Med Genet 2004; 5:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berkun Y, Ben-Chetrit E, Klar A, Ben-Chetrit E. Peritoneal adhesions and intestinal obstructions in patients with familial Mediterranean fever--are they more frequent? Semin Arthritis Rheum 2007; 36:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Granat M, Tur-Kaspa I, Zylber-Katz E, Schenker JG. Reduction of peritoneal adhesion formation by colchicine: a comparative study in the rat. Fertil Steril 1983; 40:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haimov-Kochman R, Ben-Chetrit E. The effect of colchicine treatment on sperm production and function: a review. Hum Reprod 1998; 13:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Babior BM, Matzner Y. The familial Mediterranean fever gene--cloned at last. N Engl J Med 1997; 337:1548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Booty MG, Chae JJ, Masters SL, et al. Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum 2009; 60:1851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karacan İ, Uğurlu S, Tolun A, et al. Other autoinflammatory disease genes in an FMF-prevalent population: a homozygous MVK mutation and a novel heterozygous TNFRSF1A mutation in two different Turkish families with clinical FMF. Clin Exp Rheumatol 2017; 35 Suppl 108:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997; 40:1879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yalçinkaya F, Ozen S, Ozçakar ZB, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford) 2009; 48:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozçakar ZB, Yalçınkaya F, Cakar N, et al. Application of the new pediatric criteria and Tel Hashomer criteria in heterozygous patients with clinical features of FMF. Eur J Pediatr 2011; 170:1055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kondi A, Hentgen V, Piram M, et al. Validation of the new paediatric criteria for the diagnosis of familial Mediterranean fever: data from a mixed population of 100 children from the French reference centre for auto-inflammatory disorders. Rheumatology (Oxford) 2010; 49:2200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gattorno M, Hofer M, Federici S, et al. Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis 2019; 78:1025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shinar Y, Ceccherini I, Rowczenio D, et al. ISSAID/EMQN Best Practice Guidelines for the Genetic Diagnosis of Monogenic Autoinflammatory Diseases in the Next-Generation Sequencing Era. Clin Chem 2020; 66:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soriano A, Manna R. Familial Mediterranean fever: new phenotypes. Autoimmun Rev 2012; 12:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samuels J, Aksentijevich I, Torosyan Y, et al. Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore) 1998; 77:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Padeh S, Shinar Y, Pras E, et al. Clinical and diagnostic value of genetic testing in 216 Israeli children with Familial Mediterranean fever. J Rheumatol 2003; 30:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben-Zvi I, Herskovizh C, Kukuy O, et al. Familial Mediterranean fever without MEFV mutations: a case-control study. Orphanet J Rare Dis 2015; 10:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Gorp H, Huang L, Saavedra P, et al. Blood-based test for diagnosis and functional subtyping of familial Mediterranean fever. Ann Rheum Dis 2020; 79:960.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magnotti F, Malsot T, Georgin-Lavialle S, et al. Fast diagnostic test for familial Mediterranean fever based on a kinase inhibitor. Ann Rheum Dis 2021; 80:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erdogan M, Ugurlu S, Ozdogan H, Seyahi E. Familial Mediterranean fever: misdiagnosis and diagnostic delay in Turkey. Clin Exp Rheumatol 2019; 37 Suppl 121:119.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2635 Version 33.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5340644" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Familial Mediterranean fever. A survey of 470 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16755655" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The prodrome: a prominent yet overlooked pre-attack manifestation of familial Mediterranean fever.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The effect of pregnancy on disease course in FMF
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31694745" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Familial Mediterranean fever: different faces around the world.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25261100" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Genotype-phenotype correlation in Japanese patients with familial Mediterranean fever: differences in genotype and clinical features between Japanese and Mediterranean populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19790133" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Familial mediterranean Fever in the world.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20194447" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Familial Mediterranean fever in children presenting with attacks of fever alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1295087" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The arthritis of familial Mediterranean fever.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16265718" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The arthritis of familial Mediterranean fever.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/866903" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Protracted arthritis in familial Mediterranean fever.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22243424" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Erysipelas-like erythema as the presenting feature of familial Mediterranean fever.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2217666" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The cutaneous manifestations in children with familial Mediterranean fever (recurrent hereditary polyserositis). A six-year study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25669438" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Risk factors for subclinical inflammation in children with Familial Mediterranean fever.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25649364" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Familial Mediterranean Fever.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9415347" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Attacks of pericarditis as a manifestation of familial Mediterranean fever (FMF).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11742050" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Hereditary periodic fever.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8044614" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Acute scrotal pain complicating familial Mediterranean fever in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15965640" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Familial Mediterranean fever protracted febrile myalgia in children: report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7799354" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Protracted febrile myalgia in patients with familial Mediterranean fever.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24064026" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Is recurrent aseptic meningitis a manifestation of familial Mediterranean fever? A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18512793" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25761640" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Non-canonical manifestations of familial Mediterranean fever: a changing paradigm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26464521" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Non-thrombocytopenic purpura in familial Mediterranean fever-comorbidity with Henoch-Schönlein purpura or an additional rare manifestation of familial Mediterranean fever?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20669279" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Association of familial Mediterranean fever-related MEFV variations with ankylosing spondylitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31849945" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : FMF Is Associated With a Wide Spectrum of MHC Class I- and Allied SpA Disorders but Not With Classical MHC Class II-Associated Autoimmune Disease: Insights From a Large Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16511642" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Inflammatory/demyelinating central nervous system involvement in familial Mediterranean fever (FMF): coincidence or association?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16284730" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Hereditary periodic fever and reactive amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13713112" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Amyloidosis in familial Mediterranean fever. An independent genetically determined character.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5715490" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The role of amyloidosis in familial mediterranean fever. A population study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9500348" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Familial Mediterranean fever.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15643295" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24369413" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Amyloidosis and its related factors in Turkish patients with familial Mediterranean fever: a multicentre study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17469185" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9288758" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15018633" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Amyloidosis in familial Mediterranean fever patients: correlation with MEFV genotype and SAA1 and MICA polymorphisms effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17240429" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Peritoneal adhesions and intestinal obstructions in patients with familial Mediterranean fever--are they more frequent?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6884539" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Reduction of peritoneal adhesion formation by colchicine: a comparative study in the rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9557838" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The effect of colchicine treatment on sperm production and function: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9366590" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The familial Mediterranean fever gene--cloned at last.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19479870" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Familial Mediterranean fever with a single MEFV mutation: where is the second hit?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29148404" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Other autoinflammatory disease genes in an FMF-prevalent population: a homozygous MVK mutation and a novel heterozygous TNFRSF1A mutation in two different Turkish families with clinical FMF.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9336425" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Criteria for the diagnosis of familial Mediterranean fever.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19193696" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : A new set of criteria for the diagnosis of familial Mediterranean fever in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21287357" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Application of the new pediatric criteria and Tel Hashomer criteria in heterozygous patients with clinical features of FMF.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20688806" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Validation of the new paediatric criteria for the diagnosis of familial Mediterranean fever: data from a mixed population of 100 children from the French reference centre for auto-inflammatory disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31018962" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Classification criteria for autoinflammatory recurrent fevers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32176780" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : ISSAID/EMQN Best Practice Guidelines for the Genetic Diagnosis of Monogenic Autoinflammatory Diseases in the Next-Generation Sequencing Era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22878273" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Familial Mediterranean fever: new phenotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9715731" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12508410" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Clinical and diagnostic value of genetic testing in 216 Israeli children with Familial Mediterranean fever.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25887307" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Familial Mediterranean fever without MEFV mutations: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32312770" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Blood-based test for diagnosis and functional subtyping of familial Mediterranean fever.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33037005" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Fast diagnostic test for familial Mediterranean fever based on a kinase inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31694753" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Familial Mediterranean fever: misdiagnosis and diagnostic delay in Turkey.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
